close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc
Search

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.18 3.51

Neutraalne

Hinna uuendus 8. apr 2026, 19:36 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.1400000000000001

Max

1.22

Põhinäitajad

By Trading Economics

Sissetulek

-124K

-32M

Müük

-372K

1.4M

Aktsiakasum

-0.27

Kasumimarginaal

-2,364.792

Töötajad

161

EBITDA

-13M

-42M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+73.91% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-36M

138M

Eelmine avamishind

-2.33

Eelmine sulgemishind

1.18

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2026, 20:44 UTC

Tulu

Costco Reports 11% Growth in March Sales

DJ

Loe

8. apr 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

8. apr 2026, 23:51 UTC

Market Talk

Nikkei May Rise on Hopes for Talks to End Iran War -- Market Talk

DJ

Loe

8. apr 2026, 23:36 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Likely Technical Correction -- Market Talk

DJ

Loe

8. apr 2026, 22:56 UTC

Market Talk

Ramelius Resources May Downgrade Cost Guidance This Month -- Market Talk

DJ

Loe

8. apr 2026, 22:45 UTC

Market Talk

Constellation Brands Points to Continuing Challenges Among Hispanic Consumers -- Market Talk

DJ

Loe

8. apr 2026, 22:17 UTC

Market Talk

Applied Digital Says Its Holding Out for Quality Customers -- Market Talk

DJ

Loe

8. apr 2026, 21:52 UTC

Uudisväärsed sündmused

A Closer Look at Iran's 10 Demands -- and Which the U.S. Might Accept -- Update

DJ

Loe

8. apr 2026, 21:24 UTC

Tulu

FedEx Freight Aims for 12% Profit Growth. How That Compares to the Leader. -- Barrons.com

DJ

Loe

8. apr 2026, 21:01 UTC

Uudisväärsed sündmused

Oil Prices Tumble Despite Conflicting Reports About the Strait of Hormuz -- Barrons.com

DJ

Loe

8. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

DJ

Loe

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Is Expressing No Opinion and Is Neutral as to Whether Stockholders Should Tender Their Shrs in Response to TRC's Offer >ORCL

DJ

Loe

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle Does Not Endorse TRC's Mini-Tender Offer or the Offer Documentation >ORCL

DJ

Loe

8. apr 2026, 20:43 UTC

Omandamised, ülevõtmised, äriostud

Oracle: Offer Represents Less Than 0.04% of Outstanding Common Stk >ORCL

DJ

Loe

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle: TRC Offer Is to Purchase Up to 1M Shrs of Common Stk at $140.50/Shr in Cash >ORCL

DJ

Loe

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Received Notice of Unsolicited Mini-Tender Offer by TRC Dated March 24 >ORCL

DJ

Loe

8. apr 2026, 20:42 UTC

Omandamised, ülevõtmised, äriostud

Oracle Responds to TRC Cap Mini-Tender Offer

DJ

Loe

8. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased 49% Equity Interest in JV Related to Intel's Fab 34 in Ireland >INTC

DJ

Loe

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: $14.2B Repurchase Price Financed with Cash on Hand and a Bridge Loan of $6.5B >INTC

DJ

Loe

8. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

Intel Corp.: Repurchased JV Stake From Apollo-Managed Funds and Affiliates >INTC

DJ

Loe

8. apr 2026, 19:44 UTC

Tulu

These Companies Pay 5% Dividend Yields, and They're Hiking Them Too -- Barrons.com

DJ

Loe

8. apr 2026, 19:16 UTC

Market Talk

Hogs Follow Cutout Prices Lower -- Market Talk

DJ

Loe

8. apr 2026, 19:02 UTC

Market Talk

Global Energy Roundup: Market Talk

DJ

Loe

8. apr 2026, 19:02 UTC

Market Talk

Oil Futures Plunge as Cease-Fire Raises Hopes for Restored Supply -- Market Talk

DJ

Loe

8. apr 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Fall in Line With Slump in Oil -- Market Talk

DJ

Loe

8. apr 2026, 18:51 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

8. apr 2026, 18:51 UTC

Market Talk

Levi Strauss CEO Says Expanded Offerings, DTC Focus Are Working -- Market Talk

DJ

Loe

8. apr 2026, 18:14 UTC

Uudisväärsed sündmused

Fed Minutes Suggest a Lengthy Iran War Could Lead to Rate Hikes -- Barrons.com

DJ

Loe

8. apr 2026, 18:05 UTC

Uudisväärsed sündmused

Oil Prices Continue to Tumble After Cease-Fire Despite Slow Reopening of Strait of Hormuz -- Barrons.com

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

73.91% tõus

12 kuu keskmine prognoos

Keskmine 2 USD  73.91%

Kõrge 2 USD

Madal 2 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

3 ratings

0

Osta

3

Hoia

0

Müü

Põhineb 3 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

No Evidence

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Muud aktsiad sektorist

MDT

Medtronic PLC

88.75

↑ +2.73%

A

Agilent Technologies Inc

116.89

↑ +2.76%

VEEV

Veeva Systems Inc

166.33

↓-3.59%

HQY

HealthEquity Inc

81.95

↑ +1.22%

TLRY

Tilray Brands Inc

6.75

↑ +4.65%
help-icon Live chat